Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.
A Randomized, Double-blind, Double-dummy, Parallel Group Trial Comparing 12 Weeks Treatment With Tiotropium Inhalation Capsules 18 mcg Via the HandiHaler® Once Daily to Combivent® Inhalation Aerosol CFC MDI 2 Actuations q.i.d. in COPD Patients Currently Prescribed Combivent® Inhalation Aerosol CFC MDI
Sponsor: Boehringer Ingelheim
A PHASE4 clinical study on Pulmonary Disease, Chronic Obstructive, this trial is completed. The trial is conducted by Boehringer Ingelheim and has accumulated 9 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2024 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2023 — Jan 2024 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2023 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Jan 2018 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Jan 2018 [monthly]
Completed PHASE4
First recorded
Oct 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
For direct contact, visit the study record on ClinicalTrials.gov .